The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2025
Preliminary Investigation of the Association Between Epigenetic Aging Acceleration and Amyloid Biomarkers in Bipolar Disorder.
СтатьяПоддержка исследования: вне правительства СШАResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fries Gabriel R, De La Garza Steven, Zhao Ning O, Bass Andres W, Lima Camila N C, Kobori Nobuhide, Barichello Tatiana, Turecki Gustavo, Schulz Paul E, Diniz Breno S, Soares Jair C
Аннотация
OBJECTIVES: Bipolar disorder (BD) has been associated with an elevated risk of Alzheimer's Disease (AD). We assessed AD biomarkers in BD and tested whether epigenetic aging (EA) acceleration is associated with changes in these markers.
DESIGN, SETTING, PARTICIPANTS: Cross-sectional study of n = 58 living individuals with BD and n = 20 age- and sex-matched control participants, as well as analyses of postmortem brain samples (Brodmann area 9/46) from n = 46 individuals with BD.
MEASUREMENTS: Amyloid beta (Aβ)40, Aβ42, and total Tau levels were measured in plasma from individuals with BD and controls, and Aβ42 levels were measured in brains. EA and its acceleration (blood: GrimAge and DunedinPACE; brains: DNAmClockCortical) were estimated for all samples. Individuals with BD were split into quartiles with slower or accelerated EA if they were in the first or fourth quartiles for GrimAge acceleration (AgeAccelGrim), DunedinPACE, or DNAmClockCortical acceleration (DNAmClockCorticalAccel).
RESULTS: Individuals with BD showed a decrease in the Aβ42/40 ratio (p = 0.048) compared to controls, and a significant decrease in the Aβ42/40 ratio was also found in individuals with BD with high versus low AgeAccelGrim (p = 0.048). Brain Aβ42 levels significantly correlated with DNAmClockCorticalAccel (r2 = 0.270, p = 0.007), with those with high EA acceleration showing higher brain Aβ42 after controlling for confounders (p = 0.008).
CONCLUSIONS: Our results provide preliminary evidence that accelerated EA is associated with markers of AD in individuals with BD, suggesting it as a potential target in efforts to prevent dementia and AD in BD.
DESIGN, SETTING, PARTICIPANTS: Cross-sectional study of n = 58 living individuals with BD and n = 20 age- and sex-matched control participants, as well as analyses of postmortem brain samples (Brodmann area 9/46) from n = 46 individuals with BD.
MEASUREMENTS: Amyloid beta (Aβ)40, Aβ42, and total Tau levels were measured in plasma from individuals with BD and controls, and Aβ42 levels were measured in brains. EA and its acceleration (blood: GrimAge and DunedinPACE; brains: DNAmClockCortical) were estimated for all samples. Individuals with BD were split into quartiles with slower or accelerated EA if they were in the first or fourth quartiles for GrimAge acceleration (AgeAccelGrim), DunedinPACE, or DNAmClockCortical acceleration (DNAmClockCorticalAccel).
RESULTS: Individuals with BD showed a decrease in the Aβ42/40 ratio (p = 0.048) compared to controls, and a significant decrease in the Aβ42/40 ratio was also found in individuals with BD with high versus low AgeAccelGrim (p = 0.048). Brain Aβ42 levels significantly correlated with DNAmClockCorticalAccel (r2 = 0.270, p = 0.007), with those with high EA acceleration showing higher brain Aβ42 after controlling for confounders (p = 0.008).
CONCLUSIONS: Our results provide preliminary evidence that accelerated EA is associated with markers of AD in individuals with BD, suggesting it as a potential target in efforts to prevent dementia and AD in BD.